Takeda and CSL Behring to Develop Potential COVID-19 Hyperimmune Therapy
Singapore, April 10 -- Takeda and CSL Behring, a provider of plasma-derived and recombinant therapies based in King of Prussia, PA, on 6 April 2020 announced a partnership to develop a potential plasma-derived therapy to treat COVID-19 with the following companies:
Biotest: a provider of plasma proteins and biological drugs based in Dreieich, Germany.
Bio Products Laboratory: a UK-based supplier of plasma-derived treatments
LFB: a biopharmaceutical group based in France that develops, manufactures, and markets plasma-derived products and recombinant proteins
Octapharma: a human protein manufacturer headquartered in Lachen, Switzerland.
The companies will develop an investigational, unbranded anti-SARS-CoV-2 polyclonal hyperimmune imm...
Click here to read full article from source
To read the full article or to get the complete feed from this publication, please
Contact Us.